Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need. Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies. Brilaroxazine is a novel multimodal modulator of serotonin, dopamine and nicotinic receptors, demonstrating improved efficacy and a better side effect profile compared to other antipsychotics. The drug class is established with over $10 billion in revenues. Unmet need persists in the category, related to efficacy, side effects & drug regimen compliance. Brilaroxazine can distinguish itself in the treatment of negative symptoms. Brilaroxazine's improved profile is ex pected to carve material share from the existing market and expand into untreated patients. Secondary can didate, RP1208, is in preclinical studies for depression and obesity. Reviva is seeking acceptance of its brilaroxazine data package with existing data which if successful would allow for NDA submission to the FDA in 2026 followed by regulatory submission in other territories. Our valuation as sumes commercializa tion in the US and rest of world following regulatory approval.
